Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)

v3.24.3
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)
3 Months Ended
Sep. 30, 2024
Notes Tables  
Schedule of the Consolidated Changes in Equity

Consolidated Changes in Equity (amounts in thousands)

    

Bio-Techne Shareholders    

    

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

Income(Loss)

Total

Balances at June 30, 2024

 

158,216

$

1,582

$

820,337

$

1,325,247

$

(78,316)

$

2,068,850

Net earnings

 

 

 

33,600

 

 

33,600

Other comprehensive income (loss)

 

 

 

 

18,229

 

18,229

Common stock issued for exercise of options

 

577

 

6

 

23,224

 

(2,338)

 

 

20,892

Common stock issued for restricted stock awards

 

50

1

 

1

 

(2,646)

 

 

(2,644)

Cash dividends

 

 

 

(12,688)

 

 

(12,688)

Stock-based compensation expense

 

 

 

10,146

 

 

 

10,146

Common stock issued to employee stock purchase plan

 

35

0

 

2,227

 

 

 

2,227

Employee stock purchase plan expense

38

38

Balances at September 30, 2024

 

158,878

$

1,589

$

855,973

$

1,341,175

$

(60,087)

$

2,138,650

    

Bio-Techne Shareholders    

    

  

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

Income(Loss)

Total

Balances at June 30, 2023

 

157,642

$

1,576

$

721,543

$

1,309,461

$

(66,064)

$

1,966,516

Net earnings

 

 

 

50,993

 

 

50,993

Other comprehensive income (loss)

 

 

 

 

(11,952)

 

(11,952)

Common stock issued for exercise of options

 

633

 

6

 

12,877

 

(15,460)

 

 

(2,577)

Common stock issued for restricted stock awards

 

47

1

 

0

 

(4,768)

 

 

(4,767)

Cash dividends

 

 

 

(12,654)

 

 

(12,654)

Stock-based compensation expense

 

 

 

9,981

 

 

 

9,981

Common stock issued to employee stock purchase plan

 

33

1

 

2,093

 

 

 

2,094

Employee stock purchase plan expense

112

112

Balances at September 30, 2023

 

158,355

$

1,584

$

746,606

$

1,327,572

$

(78,016)

$

1,997,746

Schedule of changes in Accumulated Other Comprehensive Income (Loss)

Three months ended September 30, 2024 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2024, net of tax

$

8,102

$

(86,418)

$

(78,316)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

(5,010)

20,659

15,649

Amounts reclassified out

2,599

782

3,381

Total other comprehensive income (loss), before tax

(2,411)

21,441

19,030

Tax (expense)/benefit

(616)

(185)

(801)

Total other comprehensive income (loss), net of tax

 

(3,027)

21,256

18,229

Balance as of September 30, 2024, net of tax

$

5,075

$

(65,162)

$

(60,087)

Three months ended September 30, 2023 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2023 net of tax:

$

12,862

$

(78,926)

$

(66,064)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

1,587

(11,069)

(9,482)

Amounts reclassified out

(2,539)

(698)

(3,237)

Total other comprehensive income (loss), before tax

(952)

(11,767)

(12,719)

Tax (expense)/benefit

(602)

(165)

(767)

Total other comprehensive income (loss), net of tax

 

(350)

(11,602)

(11,952)

Balance as of September 30, 2023, net of tax

$

12,512

$

(90,528)

$

(78,016)